



Chlorambucil

Chronische Lymphatische Leukämie (CLL) » + Obinutuzumab (Gazyvaro®) » Erstlinie, ≥ 65 Jahre, alle

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Chlorambucil + Obinutuzumab, CLL, first line, ≥ 65 years, all ... 2


Chlorambucil

Dokument: Fact Sheet

Spezifizierung: Chronische Lymphatische Leukämie (CLL) » + Obinutuzumab (Gazyvaro®) »
Erstlinie, ≥65 Jahre, alle

Stand: Oktober 2020

1 Chlorambucil + Obinutuzumab, CLL, first line, ≥65 years, all

Chlorambucil + Obinutuzumab, CLL, first line, ≥65 years, all																																																							
		Facts	Appraisal																																																				
		EU Approval 2019																																																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Parameter</th> <th style="text-align: left;">Results¹¹</th> <th style="text-align: left;">HR¹²</th> <th style="text-align: left;">p value</th> </tr> </thead> <tbody> <tr> <td>RR²</td> <td>81.0 vs 91.2</td> <td></td> <td>p = 0.0046</td> </tr> <tr> <td>PFS³</td> <td>22.2 vs n.r.¹⁵</td> <td>0.23</td> <td>p < 0.0001</td> </tr> <tr> <td>OS⁵</td> <td>n.r.¹⁵ vs n.r.¹⁵</td> <td></td> <td>n.s.¹³</td> </tr> <tr> <td>SAE⁷</td> <td>70 vs 68</td> <td></td> <td>n.s.¹³</td> </tr> </tbody> </table>	Parameter	Results ¹¹	HR ¹²	p value	RR ²	81.0 vs 91.2		p = 0.0046	PFS ³	22.2 vs n.r. ¹⁵	0.23	p < 0.0001	OS ⁵	n.r. ¹⁵ vs n.r. ¹⁵		n.s. ¹³	SAE ⁷	70 vs 68		n.s. ¹³	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 10%;"></th> <th style="width: 10%;">5</th> <th style="width: 10%;">4</th> <th style="width: 10%;">3b</th> <th style="width: 10%;">3a</th> <th style="width: 10%;">2c</th> <th style="width: 10%;">2b</th> <th style="width: 10%;">2a</th> <th style="width: 10%;">1b</th> <th style="width: 10%;">1a</th> </tr> </thead> <tbody> <tr> <td>Evidence (LoE)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 10%;"></th> <th style="width: 10%;">1</th> <th style="width: 10%;">2</th> <th style="width: 10%;">3</th> <th style="width: 10%;">4</th> <th style="width: 10%;">5</th> </tr> </thead> <tbody> <tr> <td>Clinical benefit (ESMO MCBS)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <p style="font-size: small; margin-top: 5px;"> ■ curative ■ non-curative </p>				5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)											1	2	3	4	5	Clinical benefit (ESMO MCBS)					
Parameter	Results ¹¹	HR ¹²	p value																																																				
RR ²	81.0 vs 91.2		p = 0.0046																																																				
PFS ³	22.2 vs n.r. ¹⁵	0.23	p < 0.0001																																																				
OS ⁵	n.r. ¹⁵ vs n.r. ¹⁵		n.s. ¹³																																																				
SAE ⁷	70 vs 68		n.s. ¹³																																																				
	5	4	3b	3a	2c	2b	2a	1b	1a																																														
Evidence (LoE)																																																							
	1	2	3	4	5																																																		
Clinical benefit (ESMO MCBS)																																																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="width: 15%;">Patients</td> <td>≥65 years, <65 years with comorbidities</td> </tr> <tr> <td>Trial</td> <td>iLLUMINATE, phase 3</td> </tr> <tr> <td>Randomisation</td> <td>1 : 1</td> </tr> <tr> <td>N¹</td> <td>229</td> </tr> <tr> <td style="color: green;">New Therapy</td> <td>Ibrutinib + Obinutuzumab</td> </tr> <tr> <td style="color: red;">Control</td> <td>Chlorambucil / Obinutuzumab</td> </tr> <tr> <td>Publication</td> <td>DOI:10.1016/S1470-2045(18)30788-5</td> </tr> </tbody> </table>	Patients	≥65 years, <65 years with comorbidities	Trial	iLLUMINATE, phase 3	Randomisation	1 : 1	N ¹	229	New Therapy	Ibrutinib + Obinutuzumab	Control	Chlorambucil / Obinutuzumab	Publication	DOI:10.1016/S1470-2045(18)30788-5	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 10%;"></th> <th style="width: 10%;">lower</th> <th style="width: 10%;">proven</th> <th style="width: 10%;">not quantifiable</th> <th style="width: 10%;">not minor</th> <th style="width: 10%;">considerable</th> <th style="width: 10%;">major</th> </tr> </thead> <tbody> <tr> <td>Additional benefit (G-BA)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>suitable for treatment with FCR</td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>not suitable for treatment with FCR</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>del17p/TP53mut</td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table>				lower	proven	not quantifiable	not minor	considerable	major	Additional benefit (G-BA)							suitable for treatment with FCR							not suitable for treatment with FCR							del17p/TP53mut									
Patients	≥65 years, <65 years with comorbidities																																																						
Trial	iLLUMINATE, phase 3																																																						
Randomisation	1 : 1																																																						
N ¹	229																																																						
New Therapy	Ibrutinib + Obinutuzumab																																																						
Control	Chlorambucil / Obinutuzumab																																																						
Publication	DOI:10.1016/S1470-2045(18)30788-5																																																						
	lower	proven	not quantifiable	not minor	considerable	major																																																	
Additional benefit (G-BA)																																																							
suitable for treatment with FCR																																																							
not suitable for treatment with FCR																																																							
del17p/TP53mut																																																							

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹¹ results for control, results for new therapy

¹² hazard ratio for new therapy

¹³ n. s. not significant

¹⁵ n. r. - median not reached